Document:

EX-10.1

 Exhibit 10.1 

AMENDMENT AND EXTENSION TO 

EMPLOYMENT AGREEMENT 

THIS AMENDMENT AND EXTENSION TO EMPLOYMENT
AGREEMENT (the “Amendment”) is entered into and effective on January 8, 2014 (the “Effective Date”), and as of the Effective Date amends and extends the
Employment Agreement dated January 8, 2008 by and between ZIOPHARM ONCOLOGY, INC. (hereinafter the “Company”), and Jonathan J. Lewis (hereinafter “Executive”)
otherwise scheduled to expire on January 8, 2014 (the “Employment Agreement”). All capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Employment Agreement. 

RECITALS 

WHEREAS, the previously extended Term of the Employment Agreement is scheduled to expire on
January 8, 2014, and the Company and Executive each desire that Executive’s employment with the Company continue to be governed by terms and conditions of the Employment Agreement for an additional one year period, which period may be
further extended by mutual written agreement of Executive and the Company following further deliberations among Executive and the Company’s Board of Directors (or, if applicable, the Compensation Committee thereof). 

WHEREAS, the Company and Executive also wish to amend the Employment Agreement as of the Effective Date
to reflect: (i) that upon any termination of Executive’s employment, any then accrued and unused vacation will be timely paid to Executive, and (ii) that during the Term Executive’s accrued and unused vacation may be carried
forward to future calendar years, subject to the limitations and pursuant to the terms of the Company’s generally applicable vacation policy, and (iii) compliance with the requirements of Section 409A of the Internal Revenue Code to
the extent applicable to Executive’s severance benefits. 
 NOW, THEREFORE, the
Company and Executive, in consideration of the mutual promises set forth herein, agree that the Employment Agreement is hereby amended as of the Effective Date as follows: 

ARTICLE 1 
 AMENDMENTS

 1.1 Extension of Term. The “Term” of Executive’s employment under the Agreement shall be extended for a period
of one (1) year expiring on January 8, 2015, which period may be further extended by mutual written agreement of Executive and the Company following further deliberations among Executive and the Company’s Board of Directors (or, if
applicable, the Compensation Committee thereof). 

  
 1. 

 1.2 Vacation Benefit Changes. Section 5(g) of the Employment Agreement is hereby
amended and restated in its entirety as follows: 
 “Vacation. The Executive shall, during the Term, be entitled to a vacation of
four (4) weeks per annum, in addition to holidays observed by the Company. During the Term, the Executive shall be entitled to carry forward accrued and unused vacation to the next year of employment, subject to the limitations and pursuant to
the terms of the Company’s generally applicable vacation policy. Notwithstanding anything to the contrary set forth in Section 10 of this Agreement or elsewhere in this Agreement, upon any termination of Executive’s employment, the
Company will provide timely payment to Executive in settlement of any then accrued but unused vacation.” 
 1.3 Section 409A
Compliance Amendment. Section 10(h) of the Agreement is hereby amended and restated in its entirety as follows: 
 “Subject to
the provisions below, the time for payment of amounts due following the Executive’s termination of employment pursuant to this Section 10 shall be determined in accordance with the Company’s regular payroll and bonus payment
practices. Subject to the provisions below, payments of Base Salary following separation from service shall be made semi-monthly at the same times as, and in accordance with, the Company’s regular payroll payments. Payments for Performance
Bonus, Discretionary Bonus or expense reimbursements accrued with respect to periods of service completed prior to the Executive’s separation from service, but unpaid at the time of termination of employment, shall be due and payable at the
same times as they otherwise would be due in accordance with the Company’s regular expense reimbursement and bonus payment practices (i.e., Performance Bonus within the 30 day period that commences following the end of the Bonus Calculation
Year; Discretionary Bonus within the 2 month period that commences following the end of a calendar year for which bonus is granted), and payments in lieu of Performance Bonus for the Bonus Calculation Year in which termination of employment occurs
or for any Bonus Calculation Year following termination of employment, payable pursuant to Section 10(c), 10(d), or 10(e) above, shall be payable at the same time as they otherwise would be due in accordance with this Agreement if the
Executive’s employment had not terminated. 
 Notwithstanding anything to the contrary herein, the following provisions apply to the
extent severance benefits provided under this Agreement are subject to Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any
state law of similar effect (collectively “Section 409A”). Severance benefits shall not commence until Executive has a “separation from service” for purposes of Section 409A. Each installment
of severance benefits is a separate “payment” for purposes of Treas. Reg. Section 1.409A-2(b)(2)(i). If Executive is, upon separation from service, a “specified employee” for purposes of Section 409A, then, solely to
the extent necessary to avoid adverse personal tax consequences under Section 409A to Executive, the timing of the severance benefits payments shall be delayed until the earlier of (i) six (6) months and one day after Executive’s
separation from service, or (ii) Executive’s death. The severance benefits are intended to comply with the requirements of Section 409A to the extent necessary to avoid adverse personal tax consequences under Section 409A, and
any ambiguities herein shall be interpreted accordingly.” 

  
 2. 

 ARTICLE 2 

GENERAL PROVISIONS 

2.1 Impact of Amendment. Except as expressly amended by this Amendment, the terms of the Employment Agreement remain in full force and
effect. 
 2.2 Governing Law. This Agreement shall be construed and interpreted in accordance with the internal laws of the
State of New York, without giving effect to its principles of conflicts of law. 
 2.3 Validity. The invalidity or unenforceability
of any provision of this Amendment or the Employment Agreement shall not affect the validity or enforceability of any other provision of this Amendment or the Employment Agreement, which shall remain in full force and effect. 

2.4 Controlling Document. In case of conflict between any of the terms and condition of this Amendment and the Employment Agreement
herein referred to, the terms and conditions of this Amendment shall control. 
 2.5 Executive Acknowledgment. Executive
acknowledges (a) that he has consulted with or has had the opportunity to consult with independent counsel of his own choice concerning this Amendment, and has been advised to do so by the Company, and (b) that he has read and understands
the Amendment, is fully aware of its legal effect, and has entered into it freely based on his own judgment. 
 2.6
Counterparts. This Amendment may be executed in one or more counterparts, all of which taken together shall constitute one and the same document. 

[Remainder of this page intentionally left blank.] 

  
 3. 

 Executed by the parties hereto on the date(s) set forth below: 

 

			
	COMPANY:
	
	ZIOPHARM ONCOLOGY, INC.
		
	BY:	 	 /s/ Caesar J. Belbel

		 	CAESAR J. BELBEL
		 	SENIOR VICE PRESIDENT AND CHIEF LEGAL OFFICER
		
	Dated:	 	January 8, 2014
	
	EXECUTIVE:
	
	 /s/ Jonathan J. Lewis

	JONATHAN J. LEWIS
		
	Dated:	 	January 8, 2014

  
 4.EX-10.2

 Exhibit 10.2 

AMENDMENT TO 
 EMPLOYMENT
AGREEMENT 
 THIS AMENDMENT TO EMPLOYMENT
AGREEMENT (the “Amendment”) is entered into and effective on January 7, 2014 (the “Effective Date”), and as of the Effective Date amends the Employment Agreement
dated September 6, 2011 by and between ZIOPHARM ONCOLOGY, INC. (hereinafter the “Company”), and Caesar J. Belbel (hereinafter
“Executive”), (the “Employment Agreement”). 
 RECITALS 

WHEREAS, the Company and Executive wish to amend the Employment Agreement as of the Effective Date to
reflect that: (i) upon any termination of Executive’s employment, any then accrued and unused vacation will be timely paid to Executive, and (ii) during Executive’s employment the Executive’s accrued and unused vacation may
be carried forward to future calendar years, subject to the limitations and pursuant to the terms of the Company’s generally applicable vacation policy. 

NOW, THEREFORE, the Company and Executive, in consideration of the mutual promises set
forth herein, agree that the Employment Agreement is amended as of the Effective Date as follows: 
 ARTICLE 1 

AMENDMENTS 
 1.1
Vacation Benefit Changes. Section 4(f) of the Employment Agreement is hereby amended and restated in its entirety as follows: 

“Vacation and Other Benefits. Employee shall be entitled to a vacation of four (4) weeks per annum (or pro rata portion
thereof for any partial year), in addition to holidays observed by the Company as they fall on scheduled days of work. Employee shall be entitled to carry forward accrued and unused vacation to the next year of employment, subject to the limitations
and pursuant to the terms of the Company’s generally applicable vacation policy. Notwithstanding anything to the contrary set forth in Section 9 of this Agreement or elsewhere in this Agreement, upon any termination of Employee’s
employment, the Company will provide timely payment to Employee in respect of any then accrued but unused vacation. Employee shall also be entitled to the rights and benefits for which he shall be eligible under any benefit or other plans
(including, without limitation, dental, medical, medical reimbursement and hospital plans, pension plans, employee stock purchase plans, profit sharing plans, bonus plans and other so-called “fringe” benefits) as the Company shall make
available to other employees generally from time to time.” 

  
 1. 

 ARTICLE 2 

GENERAL PROVISIONS 

2.1 Impact of Amendment. Except as expressly amended by this Amendment, the terms of the Employment Agreement remain in full force and
effect. 
 2.2 Governing Law. This Agreement shall be construed, interpreted, and applied in accordance with the laws of the
Commonwealth of Massachusetts, applying to contracts fully executed and performed in the Commonwealth of Massachusetts. 
 2.3
Validity. The invalidity or unenforceability of any provision of this Amendment or the Employment Agreement shall not affect the validity or enforceability of any other provision of this Amendment or the Employment Agreement, which shall remain
in full force and effect. 
 2.4 Controlling Document. In case of conflict between any of the terms and condition of this
Amendment and the Employment Agreement herein referred to, the terms and conditions of this Amendment shall control. 
 2.5
Executive Acknowledgment. Executive acknowledges (a) that he has consulted with or has had the opportunity to consult with independent counsel of his own choice concerning this Amendment, and has been advised to do so by the Company, and
(b) that he has read and understands the Amendment, is fully aware of its legal effect, and has entered into it freely based on his own judgment. 

2.6 Counterparts. This Amendment may be executed in one or more counterparts, all of which taken together shall constitute one and the
same document. 
 [Remainder of this page intentionally left blank.] 

  
 2. 

 Executed by the parties hereto on the date(s) set forth below: 

 

			
	COMPANY:
	
	ZIOPHARM ONCOLOGY, INC.
		
	BY:	 	 /s/ Jonathan Lewis

		 	JONATHAN LEWIS, M.D., PH.D
		 	CHIEF EXECUTIVE OFFICER
		
	Dated:	 	January 7, 2014
	
	EXECUTIVE:
	
	 /s/ Caesar J. Belbel

	CAESAR J. BELBEL
		
	Dated:	 	January 7, 2014

  
 3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]